Indivumed GmbH, an International Organization for Standardization (ISO) certified global oncology research company based in Hamburg, Germany, has established the world’s leading Cancer Database and biobank, retaining unique patterns of biomolecules such as RNA, DNA, and proteins as they existed in the human body.
The Agency for Science, Technology and Research (A*STAR) is Singapore’s top public-sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. A*STAR’s Institute of Molecular and Cell Biology (IMCB) has the vision of addressing the mechanistic basis of human diseases. A*STAR’s Research Support Centre (RSC) is a one-stop support centre for all biomedical R&D needs, now including more than 20 platforms.
Indivumed and A*STAR’s Institute of Molecular and Cell Biology (IMCB) in Singapore have signed an agreement to perform proteomic and phosphoproteomic analysis of thousands of tissue samples from Indivumed’s unique biobank, “IndivuType”.
IndivuType combines comprehensive cell biological information such as genomic, transcriptomic, proteomic, precision proteomic, and digital histopathology data with extensive clinical information from thousands of patients. A portal IT solution with a variety of cutting-edge bioinformatic and artificial intelligence tools enables cancer researchers and clinicians to comprehensively analyze and understand the complexity of the disease.
“A*STAR’s IMCB in Singapore is one of the world’s leading research institutions with their cutting-edge technological platforms. We are excited that we can benefit from their outstanding scientific expertise to create highly reliable proteomic and phosphoproteomic data. This agreement is for us a major milestone in building the leading global cancer database which will open novel avenues and treatment modalities to fight this devastating malady.” – Prof. Hartmut Juhl, Founder and CEO of Indivumed.
“The high quality of Indivumed’s global biobank as well as its collection and processing standards of all tissues and clinical data, provides a unique opportunity to understand the phenotype in cancer patients. We are very proud to participate in building this global multiomics cancer database and forge a strong clinical research partnership with Indivumed in Singapore,” – Prof. Wanjin Hong, the Executive Director of A*STAR’s IMCB.
Source:
